Pfizer Inc
PFE: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$46.00 | Pnqds | Pbbvfmtkm |
Pfizer's Q4 Earnings Are Solid; Weaker-Than-Expected 2023 Guidance Is Not Overly Concerning
Pfizer reported solid fourth-quarter results but provided lower-than-expected guidance for 2023. We don’t expect any major changes to our Pfizer fair value estimate, and the stock looks undervalued, especially with the recent weak stock performance that doesn’t appear to be fully reflecting the firm’s long-term outlook.